Tenidap sodium decreases renal clearance and increases steady‐state concentrations of lithium in healthy volunteers.

Abstract

1. An open‐label, randomised placebo‐controlled study was conducted to determine the effects of tenidap sodium, a novel, cytokine‐modulating anti‐rheumatic drug, on the steady‐state concentrations and renal clearance of lithium carbonate. 2. Eighteen healthy male volunteers received 450 mg lithium carbonate twice daily for 15 days and once on day 16. On days 9‐16 subjects also received either placebo or 120 mg day‐1 tenidap 2 h prior to the morning dose of lithium. 3. Following a single dose of tenidap, the renal clearance of lithium decreased significantly by 0.36 l h‐1 (‐23%) compared with the clearance in the placebo group, which increased by 0.18 l h‐1 (+14%). Steady‐state serum lithium levels increased after a single dose of tenidap by 0.069 mEq l‐ 1 (+13%), and in the placebo group levels increased by 0.003 mEq l‐1 (+0.5%); this difference was not significant. 4. After 7 days' continuous administration of tenidap, the renal clearance of lithium had decreased by 0.38 l h‐1 (‐25%), compared with the placebo group in which clearance had increased by 0.16 l h‐1 (+12%). The steady‐state serum concentration of lithium increased by 0.208 mEq l‐1 (+39%) in the tenidap group and by 0.063 mEq l‐1 (+10%) in the placebo group. Both of these differences were significant. 5. Two subjects who received lithium plus tenidap experienced gastrointestinal side effects, compared with none of those who were administered lithium plus placebo. 6. It is recommended that serum lithium levels be monitored when tenidap and lithium are administered concomitantly.